Okay. Yes, no, I think that, that's a good point. And as I've said, the M&A that we're looking at falls into 2 categories. One is geographic, where we look for opportunities in places like Asia, where we're not as large as we'd like to be. And so we continue to look at those. And again, some of those are families, privately held. And so that actually, I would say, versus a year ago, seems to be a little bit more robust, that people are willing to start to think about selling some of those particular companies. But I would say even more so, there seems to be more activity in what I call the broadening of the portfolio. And you're absolutely right. What we're looking for are those ingredients that make us more important to our customers as we formulate, especially with these specialty product ingredients. And I would say that certainly, these companies are located in different parts of the world. There are quite a few in Europe, but they're global companies. Some are divisions of larger companies, some are owned by private equity, some are privately held, but there does seem to be some momentum there. And again, what we're looking for is what's the right fit to, again, as we formulate with our science people and yet meet the demand of the customer. So what we'll make us more important and at the same time, we're looking for the value proposition that creates value for our company strategically and for our shareholders. And so that's where the whole price value comes in. And again, it builds on the strategy to be a more important global ingredient producer, that's what we're looking to drive. But again, we continue to feel very good. We have a very strong balance sheet. And our customers are looking to us to grow, and we believe that there are opportunities both organically and M&A to do that.